Pin Li

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	Utility based approach in individualized optimal dose selection using machine learning methods	2022	Pin Li Jeremy M. G. Taylor Philip S. Boonstra Theodore S. Lawrence Matthew J. Schipper
+ PDF Chat	Bayesian inference of dependent kappa for binary ratings	2021	Ananda Sen Pin Li Wen Ye Alfred Franzblau
+ PDF Chat	Evaluation of predictive model performance of an existing model in the presence of missing data	2021	Pin Li Jeremy M. G. Taylor Daniel E. Spratt R. Jeffery Karnes Matthew J. Schipper
+	TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy	2020	Pin Li Rachael Liu Jianchang Lin Yuan Ji
+	Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy	2020	Rachael Liu Jianchang Lin Pin Li
+	Use and Evaluation of Statistical Methods for Personalized Medicine in Oncology	2020	Pin Li
+ PDF Chat	A utility approach to individualized optimal dose selection using biomarkers	2019	Pin Li Jeremy M. G. Taylor Spring Kong Shruti Jolly Matthew J. Schipper

Common Coauthors

Coauthor	Papers Together
Matthew J. Schipper	3
Jeremy M. G. Taylor	3
Jianchang Lin	2
Rachael Liu	2
Philip S. Boonstra	1
Theodore S. Lawrence	1
Spring Kong	1
Ananda Sen	1
Alfred Franzblau	1
Shruti Jolly	1
Daniel E. Spratt	1
Yuan Ji	1
Wen Ye	1
R. Jeffery Karnes	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs	2004	Peter F. Thall John D. Cook	4
+ PDF Chat	Estimating Individualized Treatment Rules Using Outcome Weighted Learning	2012	Ying‐Qi Zhao Donglin Zeng A. John Rush Michael R. Kosorok	3
+ PDF Chat	The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies	2016	Jonathan Brajtbord Michael Leapman Matthew R. Cooperberg	2
+	The Bayesian Lasso	2008	Trevor Park George Casella	2
+ PDF Chat	A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2	2017	Wentian Guo Sue‐Jane Wang Shengjie Yang Henry Lynn Yuan Ji	2
+	Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials	2016	Daniel H. Li James B. Whitmore Wentian Guo Yuan Ji	2
+	Multiple imputation using chained equations: Issues and guidance for practice	2010	Ian R. White Patrick Royston Angela Wood	2
+	Regression Shrinkage and Selection Via the Lasso	1996	Robert Tibshirani	2
+ PDF Chat	Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: With an Application to Treating Type 2 Diabetes Patients With Insulin Therapies	2017	Yuanjia Wang Haoda Fu Donglin Zeng	2
+	Doubly Robust Estimation in Missing Data and Causal Inference Models	2005	Heejung Bang James M. Robins	2
+ PDF Chat	Utility‐Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials	2009	Nadine Houedé Peter F. Thall Hoang Q. Nguyen Xavier Paolettí Andrew Kramar	2
+ PDF Chat	Joint Regression Analysis of Correlated Data Using Gaussian Copulas	2008	Peter X.‐K. Song Mingyao Li Ying Yuan	2
+ PDF Chat	Dealing with Missing Predictor Values When Applying Clinical Prediction Models	2009	Kristel J.M. Janssen Yvonne Vergouwe A. Rogier T. Donders Frank E. Harrell Qingxia Chen Diederick E. Grobbee Karel G.M. Moons	2
+ PDF Chat	A review of tree-based Bayesian methods	2017	Antonio R. Linero	2
+ PDF Chat	Bayesian optimal interval designs for phase I clinical trials	2014	Suyu Liu Ying Yuan	2
+	Comparative review of novel model‐assisted designs for phase I clinical trials	2018	Heng Zhou Thomas A. Murray Haitao Pan Ying Yuan	2
+	Lasso and general L1-regularized regression under linear equality and inequality constraints	2011	Tianhong He	2
+	Review of inverse probability weighting for dealing with missing data	2011	Shaun R. Seaman Ian R. White	2
+	Quality adjusted survival analysis	1990	Paul Glasziou R. John Simes Richard D. Gelber	2
+ PDF Chat	The i3+3 design for phase I clinical trials	2019	Meizi Liu Sue-Jane Wang Yuan Ji	2
+ PDF Chat	Prospective prediction in the presence of missing data	2002	Guillermo Marshall Bradley A. Warner Samantha MaWhinney Karl E. Hammermeister	2
+	A Test of Missing Completely at Random for Multivariate Data with Missing Values	1988	Roderick J. A. Little	2
+ PDF Chat	A utility approach to individualized optimal dose selection using biomarkers	2019	Pin Li Jeremy M. G. Taylor Spring Kong Shruti Jolly Matthew J. Schipper	2
+	Bayesian Semi-parametric Design (BSD) for adaptive dose-finding with multiple strata	2020	Mo Li Rachael Liu Jianchang Lin Veronica Bunn Hongyu Zhao	2
+ PDF Chat	Personalized dose selection in radiation therapy using statistical models for toxicity and efficacy with dose and biomarkers as covariates	2014	Matthew J. Schipper Jeremy M. G. Taylor Randall K. Ten Haken Martha M. Matuzak Feng‐Ming Kong Theodore S. Lawrence	2
+ PDF Chat	Handling missing predictor values when validating and applying a prediction model to new patients	2020	Jeroen Hoogland Marit van Barreveld Thomas P. A. Debray Johannes B. Reitsma Tom E. Verstraelen Marcel G. W. Dijkgraaf Aeilko H. Zwinderman	2
+ PDF Chat	Subgroup identification from randomized clinical trial data	2011	Jared C. Foster Jeremy M. G. Taylor Stephen J. Ruberg	2
+	Using the outcome for imputation of missing predictor values was preferred	2006	Karel G.M. Moons Rogier Donders Theo Stijnen Frank E. Harrell	2
+	Robust Estimation of Area Under ROC Curve Using Auxiliary Variables in the Presence of Missing Biomarker Values	2010	Qi Long Xiaoxi Zhang Brent A. Johnson	2
+	A geometric approach to assess bias due to omitted covariates in generalized linear models	1993	John Neuhaus Nicholas P. Jewell	2
+ PDF Chat	A modified toxicity probability interval method for dose-finding trials	2010	Yuan Ji Ping Liu Yisheng Li B. Nebiyou Bekele	2
+ PDF Chat	The estimation and use of predictions for the assessment of model performance using large samples with multiply imputed data	2015	Angela Wood Patrick Royston Ian R. White	2
+	Assessing the Performance of Prediction Models	2009	Ewout W. Steyerberg Andrew J. Vickers Nancy R. Cook Thomas A. Gerds Mithat Gönen Nancy A. Obuchowski Michael Pencina Michael W. Kattan	2
+	Statistical Analysis With Missing Data	1989	Maureen Lahiff Roderick J. A. Little Donald B. Rubin	2
+	Assay Validation Using the Concordance Correlation Coefficient	1992	Lawrence I‐Kuei Lin	1
+	Extension of the Kappa Coefficient	1980	Helena C. Kraemer	1
+	Bayesian Additive Regression Trees	2006	Hugh Chipman Edward I. George Robert E. McCulloch	1
+	Testing the Homogeneity of Kappa Statistics	1996	Allan Donner Michael Eliasziw Neil Klar	1
+	Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials	2016	Ying Yuan Kenneth R. Hess Susan G. Hilsenbeck Mark R. Gilbert	1
+ PDF Chat	Personalized Dose Finding Using Outcome Weighted Learning	2016	Guanhua Chen Donglin Zeng Michael R. Kosorok	1
+ PDF Chat	A robust two‐stage design identifying the optimal biological dose for phase I/II clinical trials	2016	Yong Zang J. Jack Lee	1
+	Bayesian Phase I/II Biomarker-Based Dose Finding for Precision Medicine With Molecularly Targeted Agents	2016	Beibei Guo Ying Yuan	1
+	VARIABLE SELECTION IN REGRESSION MODELS	2013	M. Sudarsana Rao M.Sunitha M.Venkataramanaih	1
+ PDF Chat	Algorithms for Fitting the Constrained Lasso	2018	Brian R. Gaines Juhyun Kim Hua Zhou	1
+	Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials	2017	Jianchang Lin Veronica Bunn	1
+ PDF Chat	Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials	2017	Fangrong Yan Sumithra J. Mandrekar Ying Yuan	1
+	STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials	2017	Ruitao Lin Guosheng Yin	1
+	On causal estimation using $U$-statistics	2017	Lu Mao	1
+ PDF Chat	Decision making and uncertainty quantification for individualized treatments using Bayesian Additive Regression Trees	2017	Brent R. Logan Rodney Sparapani Robert E. McCulloch Purushottam W. Laud	1
+	Accuracy, Safety, and Reliability of Novel Phase I Trial Designs	2018	Heng Zhou Ying Yuan Lei Nie	1